Dengue virus serotype 4 antigens (DENV-4 antigens)

Dengue virus serotype 4 (DENV-4) antigens consist of the structural and non-structural proteins encoded by the virus that are recognized by the host immune system. The primary structural antigen is the Envelope (E) protein, a glycoprotein responsible for viral attachment to host receptors and membrane fusion, making it the central target for neutralizing antibodies. Other key antigens include the Pre-membrane (prM) protein and Non-structural protein 1 (NS1), which is a secreted biomarker involved in viral replication and the modulation of the host immune response. These antigens are critical components of tetravalent vaccines like Dengvaxia and Qdenga, which are designed to provide balanced protection against all four dengue serotypes. In clinical practice, DENV-4 antigens are targeted to prevent the progression of dengue fever into more severe forms such as dengue hemorrhagic fever or dengue shock syndrome. However, a significant challenge in targeting these antigens is antibody-dependent enhancement (ADE), where sub-neutralizing antibodies can inadvertently facilitate viral entry into immune cells, potentially exacerbating the severity of the infection.

Other names

DENV-4 proteinsDengue virus type 4 antigensDENV4 antigensDengue virus serotype 4 polyprotein

Vaccines utilize these antigens to elicit neutralizing antibodies and T-cell responses to prevent infection, while therapeutic monoclonal antibodies bind to specific epitopes on the Envelope protein to block viral attachment and fusion with host cell membranes.